Patents by Inventor John L. Magnani

John L. Magnani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS
    Publication number: 20160243145
    Abstract: Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E-selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound.
    Type: Application
    Filed: September 29, 2014
    Publication date: August 25, 2016
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, John M. PETERSON, Ingrid G. WINKLER
  • Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells
    Publication number: 20160184339
    Abstract: Methods are provided herein for use of E-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 30, 2016
    Applicant: GLYCOMIMETICS, INC.
    Inventor: John L. MAGNANI
  • E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20160145290
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selection antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 26, 2016
    Inventors: John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
  • E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE
    Publication number: 20150284420
    Abstract: Provided herein are E-selectin antagonist therapeutic agents and improvements thereto and compositions comprising these E-selectin antagonists. Methods are also provided for using these E-selectin antagonist therapeutic agents to treat and/or prevent diseases and disorders treatable by inhibiting binding of an E-selectin to an E-selectin ligand. Also provided herein improvements to E-selectin antagonist glycomimetic compounds that improve the oral bioavailability of the glycomimetic compounds.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 8, 2015
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, John M. Peterson
  • E-selectin antagonist compounds, compositions, and methods of use
    Patent number: 9109002
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 18, 2015
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20150110808
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Application
    Filed: December 21, 2012
    Publication date: April 23, 2015
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY
    Publication number: 20150051164
    Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventor: John L. Magnani
  • Pan-selectin inhibitor with enhanced pharmacokinetic activity
    Patent number: 8895510
    Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: November 25, 2014
    Assignee: Glycomimetics, Inc.
    Inventor: John L. Magnani
  • HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS
    Publication number: 20140178303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV
    Publication number: 20140073594
    Abstract: Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.
    Type: Application
    Filed: November 15, 2013
    Publication date: March 13, 2014
    Applicant: GlycoMimetics, Inc.
    Inventors: John L. Magnani, Arun K. Sarkar
  • Heterobifunctional pan-selectin inhibitors
    Patent number: 8633303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 21, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • ANTI-EPILEPTOGENIC AGENTS
    Publication number: 20130261070
    Abstract: Methods and medicaments therefor are provided for altering an epileptic syndrome in an individual. Methods and medicaments therefor are also provided for preventing an epileptic syndrome in an individual at risk for developing an epileptic syndrome. More specifically, the use of particular glycomimetics for the treatment or prevention is described.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 3, 2013
    Inventors: John L. Magnani, Rachel K. King
  • Compounds and methods for inhibiting selectin-mediated function
    Patent number: 8530448
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: September 10, 2013
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Leonard M. Williams
  • Treatment of cancers of the blood using selected glycomimetic compounds
    Patent number: 8518896
    Abstract: Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual the myeloablative bone marrow toxicities of chemotherapy.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: August 27, 2013
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Theodore A. G. Smith
  • Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
    Patent number: 8410066
    Abstract: Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: April 2, 2013
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, Arun K. Sarkar
  • Compounds and methods for treatment of sickle cell or complications associated therewith
    Patent number: 8361975
    Abstract: Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: January 29, 2013
    Assignee: Glycomimetics, Inc.
    Inventor: John L. Magnani
  • GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS
    Publication number: 20120329755
    Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.
    Type: Application
    Filed: August 3, 2012
    Publication date: December 27, 2012
    Applicant: GlycoMimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar
  • Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from
    Patent number: 8258290
    Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: September 4, 2012
    Assignee: GlycoMimetics, Inc.
    Inventors: John L Magnani, John T Patton, Jr., Arun K Sarkar
  • METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES
    Publication number: 20120202762
    Abstract: Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either.
    Type: Application
    Filed: September 2, 2011
    Publication date: August 9, 2012
    Applicant: GlycoMimetics, Inc.
    Inventor: John L. MAGNANI
  • Heterobifunctional pan-selectin inhibitors
    Patent number: RE44778
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: February 25, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst